INCIDENCE OF CARDIOVASCULAR EVENTS AMONG REAL-WORLD PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE RECEIVING ASPIRIN

Based in part on the pivotal COMPASS trial, “vascular dose” rivaroxaban (2.5 mg twice/day) (+ aspirin [ASA]) was recently approved to reduce risk of cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral arterial disease (PAD). As patients in clinical